Broken redirects

Jump to navigation Jump to search

The following redirects link to non-existent pages:

Showing below up to 50 results in range #2,241 to #2,290.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Template:Commonscat1RTemplate:Commonscat1
  2. WikiDoc News: Today In MedicineTemplate:WikiDoc News: Today In Medicine
  3. Getting Started VideoHelp:Getting started video
  4. Insert imageHelp:Images
  5. Insert imagesHelp:Images
  6. How to insert imagesHelp:Images
  7. How to insert imageHelp:Images
  8. LinkingHelp:Links
  9. NOTOCHelp:Section
  10. HelpHelp:Who what where why how
  11. Alkyl and aryl transferasesCategory:EC 2.5
  12. Nitrogenous group transferasesCategory:EC 2.6
  13. Carbon-carbon double bond isomerasesCategory:EC 5.3.3
  14. Sulfur-sulfur bond isomerasesCategory:EC 5.3.4
  15. Phosphotransferases (phosphomutases)Category:EC 5.4.2
  16. Amide synthasesCategory:EC 6.3.1
  17. Carbon-nitrogen ligases with glutamine as amide-n-donorCategory:EC 6.3.5
  18. AMI:Fixing the GAP-Quality Improvement Program for AMI Shown to be EffectiveSpecial:Badtitle/NS100:AMI:Fixing the GAP-Quality Improvement Program for AMI Shown to be Effective
  19. A large study demonstrates no gender differences in short- and long-term outcomes following PCISpecial:Badtitle/NS100:A large study demonstrates no gender differences in short- and long-term outcomes following PCI
  20. A meta-analysis of over 180,000 patients suggests that drug eluting stents are safe for both on-label and off-label useSpecial:Badtitle/NS100:A meta-analysis of over 180,000 patients suggests that drug eluting stents are safe for both on-label and off-label use
  21. Abciximab in addition to a high loading dose of clopidogrel does not improve outcomes in STEMI patients: Results from the BRAVE-3 TrialSpecial:Badtitle/NS100:Abciximab in addition to a high loading dose of clopidogrel does not improve outcomes in STEMI patients: Results from the BRAVE-3 Trial
  22. Abnormal pressure gradient distal to the implanted bare metal stent is associated with the occurrence of in-stent restenosisSpecial:Badtitle/NS100:Abnormal pressure gradient distal to the implanted bare metal stent is associated with the occurrence of in-stent restenosis
  23. Absorbable drug eluting stents are safe up to one year in single de novo coronary artery lesionsSpecial:Badtitle/NS100:Absorbable drug eluting stents are safe up to one year in single de novo coronary artery lesions
  24. Acoustic Cardiography: New Technique for Resynchronization Device Optimization May Provide Improved OutcomesSpecial:Badtitle/NS100:Acoustic Cardiography: New Technique for Resynchronization Device Optimization May Provide Improved Outcomes
  25. Acute Myocardial Infarction with Hyperoxemic Therapy II (AMIHOT II) in ST Elevation MI with Rebuttal by Dr. StoneSpecial:Badtitle/NS100:Acute Myocardial Infarction with Hyperoxemic Therapy II (AMIHOT II) in ST Elevation MI with Rebuttal by Dr. Stone
  26. Acute ischemic stroke: a decade of education and clinical investigation isn’t enoughSpecial:Badtitle/NS100:Acute ischemic stroke: a decade of education and clinical investigation isn’t enough
  27. Adjusting Clopidogrel loading dose according to platelet reactivity monitoring is associated with a decreased rate of stent thrombosis and no increase in bleedingSpecial:Badtitle/NS100:Adjusting Clopidogrel loading dose according to platelet reactivity monitoring is associated with a decreased rate of stent thrombosis and no increase in bleeding
  28. Almost two years after implantation, Sirilimus-eluting coronary stents remain exposed to the circulation. August 11, 2007Special:Badtitle/NS100:Almost two years after implantation, Sirilimus-eluting coronary stents remain exposed to the circulation
  29. Angiomax Monotherapy Associated with Reduced Net Adverse Clinical Events, Major Bleeding and Cardiac‐Related Death Compared to Heparin Plus a Glycoprotein IIb/IIIa Inhibition in Primary PCI: Results of HORIZONS AMISpecial:Badtitle/NS100:Angiomax Monotherapy Associated with Reduced Net Adverse Clinical Events, Major Bleeding and Cardiac‐Related Death Compared to Heparin Plus a Glycoprotein IIb/IIIa Inhibition in Primary PCI: Results of HORIZONS AMI
  30. Antioxidants: WACS Study Demonstrates No Significant Benefit From Antioxidants For Preventing CVDSpecial:Badtitle/NS100:Antioxidants: WACS Study Demonstrates No Significant Benefit From Antioxidants For Preventing CVD
  31. Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty 5 (ARMYDA-5) Presented Today at TCT 2007Special:Badtitle/NS100:Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty 5 (ARMYDA-5) Presented Today at TCT 2007
  32. Antiplatelets: Clopidogrel-to-Ticlopidine Crossover Study Demonstrates Drug Specific ResistanceSpecial:Badtitle/NS100:Antiplatelets: Clopidogrel-to-Ticlopidine Crossover Study Demonstrates Drug Specific Resistance
  33. Anxious individuals are at risk for heart attacksSpecial:Badtitle/NS100:Anxious individuals are at risk for heart attacks
  34. Apixaban causes increased bleeding, but reduced ischemic events in patients with recent acute coronary syndrome: Results of the APPRAISE-1 TrialSpecial:Badtitle/NS100:Apixaban causes increased bleeding, but reduced ischemic events in patients with recent acute coronary syndrome: Results of the APPRAISE-1 Trial
  35. Arginine metabolite found to predict mortality in patients with cardiogenic shockSpecial:Badtitle/NS100:Arginine metabolite found to predict mortality in patients with cardiogenic shock
  36. Aspiration before Primary PCI Improves Outcomes: Results of EXPIRA and EXPORTSpecial:Badtitle/NS100:Aspiration before Primary PCI Improves Outcomes: Results of EXPIRA and EXPORT
  37. Atherosclerosis: Study links atherosclerosis progression to traffic exposureSpecial:Badtitle/NS100:Atherosclerosis: Study links atherosclerosis progression to traffic exposure
  38. Atrial tachyarrhythmia burden ≥5.5h in a day doubles the risk for thromboembolism in the TRENDS studySpecial:Badtitle/NS100:Atrial tachyarrhythmia burden ≥5.5h in a day doubles the risk for thromboembolism in the TRENDS study
  39. Automated External Defibrillators offer no benefit in cardiac arrests that occur at home in the HAT trialSpecial:Badtitle/NS100:Automated External Defibrillators offer no benefit in cardiac arrests that occur at home in the HAT trial
  40. BEAUTIFUL study fails to meet primary endpoint but demonstrates that heart rates can safely be reduced with IvabradineSpecial:Badtitle/NS100:BEAUTIFUL study fails to meet primary endpoint but demonstrates that heart rates can safely be reduced with Ivabradine
  41. Better to be a pear than an apple: new prospective look at associations between fat distribution and coronary heart diseaseSpecial:Badtitle/NS100:Better to be a pear than an apple: new prospective look at associations between fat distribution and coronary heart disease
  42. Biolimus Eluting Stents Shown to be as Safe and Effective as Sirolimus Eluting Stents in Everyday Clinical Practice: Results from the LEADERS TrialSpecial:Badtitle/NS100:Biolimus Eluting Stents Shown to be as Safe and Effective as Sirolimus Eluting Stents in Everyday Clinical Practice: Results from the LEADERS Trial
  43. Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trialSpecial:Badtitle/NS100:Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial
  44. Bivalirudin is no better than heparin in patients pretreated with clopidogrel undergoing PCI: Results from the ISAR-REACT-3 trialSpecial:Badtitle/NS100:Bivalirudin is no better than heparin in patients pretreated with clopidogrel undergoing PCI: Results from the ISAR-REACT-3 trial
  45. Cardiac Resynchronization Therapy and Single Center Experience Links SurvivalSpecial:Badtitle/NS100:Cardiac Resynchronization Therapy and Single Center Experience Links Survival
  46. Cardiac arrest during weekends and nights is associated with poor outcomesSpecial:Badtitle/NS100:Cardiac arrest during weekends and nights is associated with poor outcomes
  47. Cardiogenic Shock: New Treatment Options with Percutaneous Left Ventricular Assist Devices?Special:Badtitle/NS100:Cardiogenic Shock: New Treatment Options with Percutaneous Left Ventricular Assist Devices?
  48. Cardiologists’ Use of Pulmonary Artery Catheter Information in CCU Treatment DecisionsSpecial:Badtitle/NS100:Cardiologists’ Use of Pulmonary Artery Catheter Information in CCU Treatment Decisions
  49. Cardiovascular risk increases with incremental doses of celecoxibSpecial:Badtitle/NS100:Cardiovascular risk increases with incremental doses of celecoxib
  50. Changes in Residents’ Hours of Work Not Generally Reflected in Improved OutcomesSpecial:Badtitle/NS100:Changes in Residents’ Hours of Work Not Generally Reflected in Improved Outcomes

View ( | ) (20 | 50 | 100 | 250 | 500)